Iclepertin
investig.
What it isGlycine transporter type 1 inhibitor; investigational for cognitive impairment in schizophrenia.
Why this oneIt was the most advanced attempt to treat schizophrenia cognition rather than psychosis.
What limits itThe phase 3 program failed, which is now an important negative result for the glutamatergic hypothesis.
FDA-approved for
- cognitive impairment in schizophrenia (investigational)
Off-label
- cognitive impairment in schizophrenia (phase 3 failed)
NO BOXED WARNINGS
Principal riskThe schizophrenia cognition program failed in phase 3
Classes and tags
Clinical profile
Defining liabilityUnapproved efficacy; dose-related CNS/visual effects at high exposure